SPRO

+ Watchlist + Portfolio

Spero Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.23
52-Week Range: $1.08 – $3.08
Market Cap: $70.46M
P/E (TTM): 8.64
EPS (TTM): 0.14
Dividend Yield: —

Advanced Metrics

Price/Book: 1.59
PEG Ratio: —
Return on Equity: 19.17%
Return on Assets: 7.19%
Gross Margin: 56.31%
Operating Margin: 14.07%
Profit Margin: 15.71%
Current Ratio: 6.12
Debt/Equity: 0.05
Total Debt: $2.04M
Free Cash Flow: $28.85M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $21.73M

SPRO Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$48.58M	$96.73M	$27.40M	$59.62M
Research & Development	$47.59M	$51.44M	$96.76M	$38.47M
Selling, General & Admin	$36.48M	$25.55M	$23.70M	$21.18M
Operating Expenses	$79.15M	$69.95M	$99.88M	$52.46M
Operating Income	-$30.57M	$26.79M	-$72.48M	$7.16M
EBITDA	-$42.94M	$27.15M	-$72.48M	$7.16M
Pretax Income	-$46.41M	$25.40M	-$68.57M	$8.83M
Income Tax	$0.00	$2.60M	$0.00	$261.00K
Net Income	-$46.41M	$22.81M	-$68.57M	$8.57M
Diluted EPS	-1.23	0.43	-1.27	0.15
Diluted Shares	37.59M	52.99M	54.04M	59.04M

SPRO Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$109.11M	$76.33M	$52.89M	$40.27M
Receivables	$1.08M	$50.70M	$52.48M	$25.39M
Current Assets	$113.57M	$131.21M	$107.28M	$67.29M
Total Assets	$124.80M	$182.39M	$110.54M	$68.92M
Current Liabilities	$21.65M	$37.15M	$49.07M	$8.87M
Total Debt	$6.65M	$5.54M	$4.30M	$2.90M
Total Liabilities	$48.87M	$75.50M	$64.42M	$9.90M
Retained Earnings	-$413.88M	-$391.07M	-$459.64M	-$451.07M
Shareholders' Equity	$75.93M	$106.89M	$46.12M	$59.02M
Working Capital	$91.92M	$94.06M	$58.20M	$58.42M

SPRO Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$7.73M	-$32.99M	-$23.44M	-$12.62M
Free Cash Flow	-$7.73M	-$32.99M	-$23.44M	-$12.62M
Depreciation & Amortisation	$869.00K	$367.00K	$2.00K	$0.00
Stock-Based Compensation	$9.12M	$7.93M	$7.79M	$4.33M
Investing Cash Flow	$33.81M	$0.00	—	—
Financing Cash Flow	-$29.55M	$221.00K	$0.00	—
Net Change in Cash	-$3.48M	-$32.77M	-$23.44M	-$12.62M

SPRO Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$5.11M	$11.80M	$3.05M	$39.66M	$258.00K
Research & Development	$13.61M	$10.67M	$8.60M	$5.59M	$2.91M
Selling, General & Admin	$6.82M	$5.88M	$4.17M	$4.30M	$4.89M
Operating Expenses	$19.67M	$14.16M	$10.38M	$8.25M	$7.80M
Operating Income	-$14.56M	-$2.36M	-$7.33M	$31.41M	-$7.54M
EBITDA	-$14.56M	-$2.36M	-$7.33M	$31.41M	-$7.54M
Pretax Income	-$13.87M	-$1.70M	-$7.38M	$31.78M	-$7.20M
Income Tax	—	—	$0.00	$261.00K	—
Net Income	-$13.87M	-$1.70M	-$7.38M	$31.52M	-$7.20M
Diluted EPS	-0.25	-0.03	-0.13	0.53	-0.13
Diluted Shares	55.38M	56.03M	56.28M	59.37M	57.28M

SPRO Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$48.89M	$31.19M	$48.62M	$40.27M	$56.13M
Receivables	$24.28M	$26.91M	$2.46M	$25.39M	$44.00K
Current Assets	$74.71M	$59.40M	$52.32M	$67.29M	$57.61M
Total Assets	$77.71M	$62.12M	$54.17M	$68.92M	$59.02M
Current Liabilities	$29.16M	$14.95M	$13.65M	$8.87M	$5.49M
Total Debt	$3.96M	$3.62M	$3.35M	$2.90M	$2.47M
Total Liabilities	$43.90M	$29.29M	$27.68M	$9.90M	$6.09M
Retained Earnings	-$473.50M	-$475.20M	-$482.59M	-$451.07M	-$458.27M
Shareholders' Equity	$33.81M	$32.83M	$26.49M	$59.02M	$52.93M
Working Capital	$45.56M	$44.46M	$38.67M	$58.42M	$52.12M

SPRO Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$4.00M	-$17.69M	$17.42M	-$8.35M	$15.86M
Free Cash Flow	-$4.00M	-$17.69M	$17.42M	-$8.35M	$15.86M
Depreciation & Amortisation	—	—	$0.00	$0.00	—
Stock-Based Compensation	$1.56M	$714.00K	$1.05M	$1.01M	$1.11M
Net Change in Cash	-$4.00M	-$17.69M	$17.42M	-$8.35M	$15.86M

Market Snapshot

About

Spero Therapeutics is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments for multi-drug resistant bacterial infections. The company is developing novel therapies designed to address the growing global threat of antibiotic resistance.